ATE279943T1 - Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden - Google Patents

Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden

Info

Publication number
ATE279943T1
ATE279943T1 AT00902831T AT00902831T ATE279943T1 AT E279943 T1 ATE279943 T1 AT E279943T1 AT 00902831 T AT00902831 T AT 00902831T AT 00902831 T AT00902831 T AT 00902831T AT E279943 T1 ATE279943 T1 AT E279943T1
Authority
AT
Austria
Prior art keywords
improvement
bactericidal activity
oligonucleotides containing
adjuvant
neisseria antigens
Prior art date
Application number
AT00902831T
Other languages
English (en)
Inventor
Guido Grandi
Rino Rappuoli
Marzia M Giuliani
Mariagrazia Pizza
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Application granted granted Critical
Publication of ATE279943T1 publication Critical patent/ATE279943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00902831T 1999-02-26 2000-02-09 Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden ATE279943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12179299P 1999-02-26 1999-02-26
PCT/IB2000/000176 WO2000050075A2 (en) 1999-02-26 2000-02-09 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs

Publications (1)

Publication Number Publication Date
ATE279943T1 true ATE279943T1 (de) 2004-11-15

Family

ID=22398817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902831T ATE279943T1 (de) 1999-02-26 2000-02-09 Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden

Country Status (11)

Country Link
US (1) US8221761B1 (de)
EP (1) EP1154790B1 (de)
JP (2) JP4812942B2 (de)
AT (1) ATE279943T1 (de)
AU (1) AU2457100A (de)
CA (1) CA2371994C (de)
DE (1) DE60015084T2 (de)
ES (1) ES2228454T3 (de)
HK (1) HK1042425B (de)
PT (1) PT1154790E (de)
WO (1) WO2000050075A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860192A1 (de) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
ES2563677T3 (es) * 1999-05-19 2016-03-15 Glaxosmithkline Biologicals Sa Composiciones de combinaciones de Neisseria
JP4840956B2 (ja) * 1999-11-29 2011-12-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ８５ｋＤａのナイセリア抗原
NZ521396A (en) 2000-02-28 2004-06-25 Chiron S Fusion proteins comprising two or more Neisseria polypeptides
JP2004529643A (ja) 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
BR0213119A (pt) * 2001-10-03 2004-12-28 Chiron Corp Composição imunogênica e uso da mesma
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003030934A2 (en) * 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2353608B1 (de) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
MX2012013713A (es) 2010-05-26 2013-01-28 Selecta Biosciences Inc Composiciones de nanovehiculos con adyuvante no acoplado.
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (de) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69733020T2 (de) 1996-10-11 2006-02-16 The Regents Of The University Of California, Oakland Immunostimulierende oligonucleotidekonjugate
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
JP5087758B2 (ja) * 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6225292B1 (en) * 1997-06-06 2001-05-01 The Regents Of The University Of California Inhibitors of DNA immunostimulatory sequence activity
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP4918188B2 (ja) * 1997-12-16 2012-04-18 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP2210945B1 (de) * 1998-01-14 2013-06-26 Novartis Vaccines and Diagnostics S.r.l. Antigene aus Neisseria meningitidis
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
AU761780B2 (en) * 1998-05-01 2003-06-12 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) * 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
EP1144643A1 (de) * 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigen
JP2004537956A (ja) * 1999-01-22 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DE60014076T2 (de) * 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US7368261B1 (en) * 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DE60142772D1 (de) * 2000-01-17 2010-09-23 Novartis Vaccines & Diagnostic Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
NZ521396A (en) * 2000-02-28 2004-06-25 Chiron S Fusion proteins comprising two or more Neisseria polypeptides
US7767197B2 (en) * 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
US20040258702A1 (en) * 2000-06-22 2004-12-23 Blonder Joan P. Vaccine delivery
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
JP2004518631A (ja) * 2000-09-28 2004-06-24 カイロン コーポレイション 異種核酸の送達のための微粒子
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
JP2004529643A (ja) * 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
US6541554B2 (en) * 2001-05-17 2003-04-01 Milliken & Company Low-shrink polypropylene fibers
EP2545937A1 (de) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsionsimpfstoffe
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
CA2511512C (en) * 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
ES2411080T3 (es) * 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
US20050002948A1 (en) * 2003-05-07 2005-01-06 Ryall Robert P. Method of enhanced immunogenicity to meningococcal vaccination
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
WO2006089264A2 (en) * 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
AR053833A1 (es) * 2005-03-23 2007-05-23 Glaxosmithkline Biolog Sa Composicion inmunogenetica
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US20090089165A1 (en) * 2007-09-28 2009-04-02 Embarq Holdings Company, Llc System and method for a telephony upgrade credit

Also Published As

Publication number Publication date
WO2000050075A2 (en) 2000-08-31
PT1154790E (pt) 2005-03-31
DE60015084T2 (de) 2006-02-16
CA2371994A1 (en) 2000-08-31
US8221761B1 (en) 2012-07-17
EP1154790A2 (de) 2001-11-21
JP2010174044A (ja) 2010-08-12
DE60015084D1 (de) 2004-11-25
JP4812942B2 (ja) 2011-11-09
HK1042425B (zh) 2005-04-01
JP2002537353A (ja) 2002-11-05
EP1154790B1 (de) 2004-10-20
HK1042425A1 (en) 2002-08-16
AU2457100A (en) 2000-09-14
ES2228454T3 (es) 2005-04-16
WO2000050075A3 (en) 2001-01-11
CA2371994C (en) 2010-09-28

Similar Documents

Publication Publication Date Title
ATE279943T1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
DE60132474D1 (de) Ein immunostimulierendes nukleotid und ein tocol enthaltende zusammensetzung
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
SE9704546D0 (sv) Novel compounds
BR0015961A (pt) Antìgeno de neisseria de 85kda
SE9901875D0 (sv) Novel compounds
EP1379272A4 (de) Molekulare mimetika von meningokokken-b-epitopen, die die bildung funktionell wirksamer antikörper bewirken
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
DE69912827D1 (de) "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
EP2364726A3 (de) Impfstoff gegen Neisseria-Infektion
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2002024147A3 (en) Avian pneumovirus vaccine
DK1401492T3 (da) LTB4 som vaccineadjuvans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1154790

Country of ref document: EP

EEFA Change of the company name